{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:16:53Z","timestamp":1787163413893,"version":"build-2736575974"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP159934"],"award-info":[{"award-number":["OPP159934"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1211806"],"award-info":[{"award-number":["OPP1211806"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI089672"],"award-info":[{"award-number":["U19AI089672"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>\n                    Mass drug administration (MDA) with antimalarials has been shown to reduce prevalence and interrupt transmission in small populations, in populations with reliable access to antimalarial drugs, and in populations where sustained improvements in diagnosis and treatment are possible. In addition, when MDA is effective it eliminates both drug-resistant parasites and drug-sensitive parasites, which has the long-term benefit of extending the useful therapeutic life of first-line therapies for all populations, not just the focal population where MDA was carried out. However, in order to plan elimination measures effectively, it is necessary to characterize the conditions under which failed MDA could exacerbate resistance. We use an individual-based stochastic model of\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    transmission to evaluate this risk for MDA using dihydroartemisinin-piperaquine (DHA-PPQ), in populations where access to antimalarial treatments may not be uniformly high and where re-importation of drug-resistant parasites may be common. We find that artemisinin-resistance evolution at the\n                    <jats:italic>kelch13<\/jats:italic>\n                    locus can be accelerated by MDA when all three of the following conditions are met: (1) strong genetic bottlenecking that falls short of elimination, (2) re-importation of artemisinin-resistant genotypes, and (3) continued selection pressure during routine case management post-MDA. Accelerated resistance levels are not immediate but follow the rebound of malaria cases post-MDA, if this is allowed to occur. Crucially, resistance is driven by the selection pressure during routine case management post-MDA and not the selection pressure exerted during the MDA itself. Second, we find that increasing treatment coverage post-MDA increases the probability of local elimination in low-transmission regions (prevalence &lt; 2%) in scenarios with both low and high levels of drug-resistance importation. This emphasizes the importance of planning for and supporting high coverage of diagnosis and treatment post-MDA.\n                  <\/jats:p>","DOI":"10.1371\/journal.pgph.0002200","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T14:29:37Z","timestamp":1690381777000},"page":"e0002200","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Antimalarial mass drug administration in large populations and the evolution of drug resistance"],"prefix":"10.1371","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-8432","authenticated-orcid":true,"given":"Tran Dang","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-5900","authenticated-orcid":true,"given":"Thu Nguyen-Anh","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5352-7338","authenticated-orcid":true,"given":"Daniel M.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1897-1978","authenticated-orcid":true,"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0830-9630","authenticated-orcid":true,"given":"Maciej F.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"pgph.0002200.ref001","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0140-6736(19)31139-0","article-title":"Malaria eradication within a generation: ambitious, achievable, and necessary","volume":"394","author":"RGA Feachem","year":"2019","journal-title":"Lancet"},{"key":"pgph.0002200.ref002","unstructured":"Tanner M, Barrett S, Coutinho A, Elias C, Feachem R, Fontenille D, et al. Members of the WHO Strategic Advisory Group on Malaria Eradication. 20."},{"key":"pgph.0002200.ref003","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(18)30792-X","article-title":"Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme","volume":"391","author":"J Landier","year":"2018","journal-title":"Lancet"},{"key":"pgph.0002200.ref004","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4269\/ajtmh.14-0254","article-title":"Review of Mass Drug Administration for Malaria and Its Operational Challenges","volume":"93","author":"G Newby","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"pgph.0002200.ref005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12916-018-1202-8","article-title":"A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting\u2014high coverage and safety, but no significant impact on transmission.","volume":"16","author":"U Morris","year":"2018","journal-title":"BMC Med"},{"key":"pgph.0002200.ref006","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4269\/ajtmh.19-0657","article-title":"A Longitudinal Cohort to Monitor Malaria Infection Incidence during Mass Drug Administration in Southern Province, Zambia","volume":"103","author":"A Bennett","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"pgph.0002200.ref007","volume-title":"The Garki Project. Research on the epidemiology and control of malaria in the Sudan savanna of West Africa.","author":"World Health Organization","year":"1980"},{"key":"pgph.0002200.ref008","volume-title":"Mass drug administration and DDT indoor-spraying as antimalarial measures in the northern savanna of Nigeria","author":"JA Najera","year":"1973"},{"key":"pgph.0002200.ref009","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2915.1987.tb00370.x","article-title":"The influence of permethrin-impregnated bednets and mass drug administration on the incidence of Plasmodium falciparum malaria in children in Sabah, Malaysia","volume":"1","author":"JLK Hii","year":"1987","journal-title":"Med Vet Entomol"},{"key":"pgph.0002200.ref010","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0140-6736(83)90523-8","article-title":"Changes in malaria incidence after mass drug administraion in Nicaragua","volume":"2","author":"RM Garfield","year":"1983","journal-title":"Lancet"},{"key":"pgph.0002200.ref011","doi-asserted-by":"crossref","first-page":"e1002745","DOI":"10.1371\/journal.pmed.1002745","article-title":"The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial.","volume":"16","author":"L von Seidlein","year":"2019","journal-title":"PLOS Med"},{"key":"pgph.0002200.ref012","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/S2214-109X(17)30220-6","article-title":"Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study","volume":"5","author":"OJ Brady","year":"2017","journal-title":"Lancet Glob Health"},{"key":"pgph.0002200.ref013","doi-asserted-by":"crossref","first-page":"e20179","DOI":"10.1371\/journal.pone.0020179","article-title":"The Potential Contribution of Mass Treatment to the Control of Plasmodium falciparum Malaria.","volume":"6","author":"LC Okell","year":"2011","journal-title":"PLOS ONE."},{"key":"pgph.0002200.ref014","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12879-015-0887-y","article-title":"Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.","volume":"15","author":"J Gerardin","year":"2015","journal-title":"BMC Infect Dis"},{"key":"pgph.0002200.ref015","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IDR.S123887","article-title":"Multidrug-resistant malaria and the impact of mass drug administration.","volume":"11","author":"JA Zuber","year":"2018","journal-title":"Infect Drug Resist"},{"key":"pgph.0002200.ref016","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S1473-3099(16)30269-9","article-title":"Does antimalarial mass drug administration increase or decrease the risk of resistance?","volume":"17","author":"NJ White","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pgph.0002200.ref017","article-title":"Mass drug administration for malaria.","author":"E Poirot","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"pgph.0002200.ref018","volume-title":"Meeting report of the WHO Evidence Review Group on mass drug administration for malaria.","author":"WHO\/ERG\/MDA","year":"2018"},{"key":"pgph.0002200.ref019","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1016\/S2214-109X(15)00162-X","article-title":"Optimum population-level use of artemisinin combination therapies: a modelling study","volume":"3","author":"TD Nguyen","year":"2015","journal-title":"Lancet Glob Health"},{"key":"pgph.0002200.ref020","first-page":"2021.04.08.437876","article-title":"Pre-existing partner-drug resistance facilitates the emergence and spread of artemisinin resistance: a consensus modelling study","author":"OJ Watson","year":"2022","journal-title":"Lancet Microbe"},{"key":"pgph.0002200.ref021","doi-asserted-by":"crossref","first-page":"e0000111","DOI":"10.1371\/journal.pgph.0000111","article-title":"Long-term effects of increased adoption of artemisinin combination therapies in Burkina Faso","volume":"2","author":"RJ Zupko","year":"2022","journal-title":"PLoS Glob Public Health"},{"key":"pgph.0002200.ref022","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1473-3099(16)30415-7","article-title":"A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype\u2013genotype association study","volume":"17","author":"B Witkowski","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"pgph.0002200.ref023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1473-3099(18)30068-9","article-title":"Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic study","volume":"18","author":"R Amato","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pgph.0002200.ref024","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S1473-3099(19)30543-2","article-title":"Plasmodium falciparum resistance to piperaquine driven by PfCRT","volume":"19","author":"SK Dhingra","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pgph.0002200.ref025","doi-asserted-by":"crossref","first-page":"e1010926","DOI":"10.1371\/journal.ppat.1010926","article-title":"Piperaquine-resistant PfCRT mutations differentially impact drug transport, hemoglobin catabolism and parasite physiology in Plasmodium falciparum asexual blood stages","volume":"18","author":"J Okombo","year":"2022","journal-title":"PLOS Pathog"},{"key":"pgph.0002200.ref026","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-018-05652-0","article-title":"Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine.","volume":"9","author":"LS Ross","year":"2018","journal-title":"Nat Commun."},{"key":"pgph.0002200.ref027","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1093\/infdis\/jiac365","article-title":"Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials","volume":"226","author":"KJ Wicht","year":"2022","journal-title":"J Infect Dis"},{"key":"pgph.0002200.ref028","doi-asserted-by":"crossref","first-page":"e1010278","DOI":"10.1371\/journal.ppat.1010278","article-title":"Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance.","volume":"18","author":"JL Small-Saunders","year":"2022","journal-title":"PLOS Pathog."},{"key":"pgph.0002200.ref029","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/infdis\/jix334","article-title":"Association of a Novel Mutation in the Plasmodium falciparum Chloroquine Resistance Transporter With Decreased Piperaquine Sensitivity","volume":"216","author":"S Agrawal","year":"2017","journal-title":"J Infect Dis"},{"key":"pgph.0002200.ref030","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S1473-3099(19)30391-3","article-title":"Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study","volume":"19","author":"RW van der Pluijm","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"pgph.0002200.ref031","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/S2214-109X(17)30076-1","article-title":"Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003\u20132015: a modelling study using data from national surveys","volume":"5","author":"A Bennett","year":"2017","journal-title":"Lancet Glob Health"},{"key":"pgph.0002200.ref032","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.epidem.2017.02.002","article-title":"Measuring and modelling the effects of systematic non-adherence to mass drug administration.","volume":"18","author":"L Dyson","year":"2017","journal-title":"Epidemics"},{"key":"pgph.0002200.ref033","doi-asserted-by":"crossref","first-page":"e1003227","DOI":"10.1371\/journal.pmed.1003227","article-title":"A multiphase program for malaria elimination in southern Mozambique (the Magude project): A before-after study.","volume":"17","author":"B Galatas","year":"2020","journal-title":"PLOS Med"},{"key":"pgph.0002200.ref034","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4269\/ajtmh.19-0665","article-title":"Treatment Coverage Estimation for Mass Drug Administration for Malaria with Dihydroartemisinin\u2013Piperaquine in Southern Province, Zambia","volume":"103","author":"TP Finn","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"pgph.0002200.ref035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.12688\/wellcomeopenres.12240.1","article-title":"Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar.","volume":"2","author":"J Landier","year":"2017","journal-title":"Wellcome Open Res"},{"key":"pgph.0002200.ref036","doi-asserted-by":"crossref","first-page":"e41023","DOI":"10.7554\/eLife.41023","article-title":"Potential herd protection against Plasmodium falciparum infections conferred by mass antimalarial drug administrations.","volume":"8","author":"DM Parker","year":"2019","journal-title":"eLife"},{"key":"pgph.0002200.ref037","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1752-4571.2008.00067.x","article-title":"Probability of emergence of antimalarial resistance in different stages of the parasite life cycle.","volume":"2","author":"W Pongtavornpinyo","year":"2009","journal-title":"Evol Appl."},{"key":"pgph.0002200.ref038","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1475-2875-6-131","article-title":"Standardizing estimates of the Plasmodium falciparum parasite rate.","volume":"6","author":"DL Smith","year":"2007","journal-title":"Malar J"},{"key":"pgph.0002200.ref039","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/infdis\/jiw416","article-title":"Short-term Impact of Mass Drug Administration With Dihydroartemisinin Plus Piperaquine on Malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial","volume":"214","author":"TP Eisele","year":"2016","journal-title":"J Infect Dis"},{"key":"pgph.0002200.ref040","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/genetics\/16.2.97","article-title":"Evolution in Mendelian populations","volume":"16","author":"S. Wright","year":"1931","journal-title":"Genetics"},{"key":"pgph.0002200.ref041","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/genetics\/146.2.723","article-title":"The Probability of Fixation in Populations of Changing Size","volume":"146","author":"SP Otto","year":"1997","journal-title":"Genetics"},{"key":"pgph.0002200.ref042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2407137","article-title":"The Bottleneck Effect and Genetic Variability in Populations","volume":"29","author":"M Nei","year":"1975","journal-title":"Evolution"},{"key":"pgph.0002200.ref043","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1093\/jac\/dkw174","article-title":"Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.","volume":"71","author":"JS McCarthy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"pgph.0002200.ref044","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12936-016-1511-3","article-title":"A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.","volume":"15","author":"JS McCarthy","year":"2016","journal-title":"Malar J."},{"key":"pgph.0002200.ref045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.","volume":"16","author":"AP Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pgph.0002200.ref046","author":"WHO\/MPAC","year":"2019","journal-title":"WHO Malaria Policy Advisory Committee (MPAC) meeting"},{"key":"pgph.0002200.ref047","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","article-title":"Evidence of Artemisinin-Resistant Malaria in Africa","volume":"385","author":"B Balikagala","year":"2021","journal-title":"N Engl J Med"},{"key":"pgph.0002200.ref048","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","article-title":"Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda","volume":"26","author":"A Uwimana","year":"2020","journal-title":"Nat Med"},{"key":"pgph.0002200.ref049","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1314981","article-title":"Spread of Artemisinin Resistance in Plasmodium falciparum Malaria","volume":"371","author":"EA Ashley","year":"2014","journal-title":"N Engl J Med"},{"key":"pgph.0002200.ref050","first-page":"61","article-title":"K13 Propeller Mutations in Plasmodium falciparum Populations in Regions of Malaria Endemicity in Vietnam from 2009 to 2016","author":"N Thuy-Nhien","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"pgph.0002200.ref051","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/infdis\/jiv752","article-title":"Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant Allele C580Y in Guyana","volume":"213","author":"SM Chenet","year":"2016","journal-title":"J Infect Dis"},{"key":"pgph.0002200.ref052","doi-asserted-by":"crossref","first-page":"e1009133","DOI":"10.1371\/journal.ppat.1009133","article-title":"Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea.","volume":"16","author":"O Miotto","year":"2020","journal-title":"PLoS Pathog"},{"key":"pgph.0002200.ref053","doi-asserted-by":"crossref","first-page":"1041896","DOI":"10.3389\/fepid.2022.1041896","article-title":"Breaking the cycle of malaria treatment failure","volume":"2","author":"MF Boni","year":"2022","journal-title":"Front Epidemiol"},{"key":"pgph.0002200.ref054","doi-asserted-by":"crossref","first-page":"e1001984","DOI":"10.1371\/journal.pmed.1001984","article-title":"The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies.","volume":"13","author":"MF Boni","year":"2016","journal-title":"PLoS Med."},{"key":"pgph.0002200.ref055","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1073\/pnas.94.22.12106","article-title":"Evaluating treatment protocols to prevent antibiotic resistance","volume":"94","author":"S Bonhoeffer","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"pgph.0002200.ref056","doi-asserted-by":"crossref","first-page":"13285","DOI":"10.1073\/pnas.0402298101","article-title":"Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals","volume":"101","author":"CT Bergstrom","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"pgph.0002200.ref057","doi-asserted-by":"crossref","first-page":"14216","DOI":"10.1073\/pnas.0804628105","article-title":"Benefits of using multiple first-line therapies against malaria","volume":"105","author":"MF Boni","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"pgph.0002200.ref058","doi-asserted-by":"crossref","first-page":"e51773","DOI":"10.7554\/eLife.51773","article-title":"Determinants of MDA impact and designing MDAs towards malaria elimination.","volume":"9","author":"B Gao","year":"2020","journal-title":"eLife"},{"key":"pgph.0002200.ref059","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12916-015-0539-5","article-title":"Plasmodium falciparum dihydroartemisinin-piperaquine failures in Cambodia are associated with mutant K13 parasites presenting high survival rates in novel piperaquine in vitro assays: retrospective and prospective investigations.","volume":"13","author":"V Duru","year":"2015","journal-title":"BMC Med."}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0002200","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T14:30:23Z","timestamp":1690381823000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0002200"}},"subtitle":[],"editor":[{"given":"Andr\u00e9 Machado","family":"Siqueira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":59,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0002200","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.03.08.434496","asserted-by":"object"}]},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}